Recently, the group's Firehawk coronary rapamycin targeted eluting stent (hereafter referred to as "Firehawk") won the bid in India. This is the first hospital admission approval contract successfully obtained by the MicroPort Medical India subsidiary. The contract is valid for one year.
According to minimally invasive medical treatment, the Firehawk was allowed to enter an Indian public general hospital. With advanced research, testing equipment and experienced medical staff, the hospital is leading the industry in the fields of cardiovascular intervention, electrophysiology, and cerebrovascular diseases.
The MicroPort Medical India subsidiary was established on August 11, 2016 with the goal of serving the Indian market. Dr. Lin Yingqing, Vice President of MicroPort Medical International Business, said that India is one of the important strategic countries for the development of MicroPort Medical's international business. The company is pleased to see that Firehawk is recognized by local experts.
Guangzhou Zhongzhinan Supply Chain Co.,Ltd. , https://www.zhongzhinanlighting.com